Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

PURPOSE: PROSTVAC, a viral vector–based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further investigated those findings. PATIENTS AND METHODS: Patients were randomly as...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Gulley, James L., Borre, Michael, Vogelzang, Nicholas J., Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C., Pook, David W., Rathenborg, Per, Flaig, Thomas W., Carles, Joan, Saad, Fred, Shore, Neal D., Chen, Liddy, Heery, Christopher R., Gerritsen, Winald R., Priou, Frank, Langkilde, Niels C., Novikov, Andrey, Kantoff, Philip W.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2019
Subjects:
RAPID COMMUNICATION
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494360/
https://ncbi.nlm.nih.gov/pubmed/30817251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02031
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items